Download Slide 1 - Annals of Internal Medicine

From: Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of
InsulinA Randomized Trial
Ann Intern Med. 2012;156(6):405-415. doi:10.7326/0003-4819-156-6-201203200-00003
Figure Legend:
Figure 1. Study flow diagram.
DAPA = dapagliflozin; INS = insulin; OAD = oral antidiabetic drug; PLA = placebo.
* This patient received no study medication or postbaseline assessments.
Date of download: 5/13/2017
Copyright © American College of Physicians. All rights reserved.
From: Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of
InsulinA Randomized Trial
Ann Intern Med. 2012;156(6):405-415. doi:10.7326/0003-4819-156-6-201203200-00003
Figure Legend:
Figure 2.
Adjusted mean changes in HbA1c level over time (
top) and at 48 weeks (bottom).
Samples are
patients in the full analysis set with nonmissing baseline values and nonmissing values for a given time point. Sample sizes at time 0 are 193, 202, 211, and 193 for the PLA, 2.5-mg DAPA, 5-mg DAPA, and 10-mg DAPA
groups, respectively. Treatment group symbols are shifted horizontally to prevent the error bars from overlapping. DAPA = dapagliflozin; HbA1c = hemoglobin A1c; INS = insulin; PLA = placebo.
Date of download: 5/13/2017
Copyright © American College of Physicians. All rights reserved.
From: Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of
InsulinA Randomized Trial
Ann Intern Med. 2012;156(6):405-415. doi:10.7326/0003-4819-156-6-201203200-00003
Figure Legend:
Figure 3.
Adjusted mean changes in total body weight over time (top) and at 48 weeks (bottom).
Samples are patients in the full analysis set with nonmissing baseline values and nonmissing values for a given time point. Sample sizes at time 0 are 193, 202, 211, and 193 for the PLA, 2.5-mg DAPA, 5-mg DAPA, and 10mg DAPA groups, respectively. Treatment group symbols are shifted horizontally to prevent the error bars from overlapping. DAPA = dapagliflozin; INS = insulin; PLA = placebo.
Date of download: 5/13/2017
Copyright © American College of Physicians. All rights reserved.
From: Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of
InsulinA Randomized Trial
Ann Intern Med. 2012;156(6):405-415. doi:10.7326/0003-4819-156-6-201203200-00003
Figure Legend:
Appendix Figure
1. Adjusted mean changes in daily insulin dose over time (top) and at 48 weeks (bottom).
Samples are patients in the full analysis set with nonmissing baseline values and nonmissing values for a given time point. Sample sizes at time 0 are 191, 200, 209, and 194 for the PLA, 2.5-mg DAPA, 5-mg DAPA, and 10mg DAPA groups, respectively. Treatment group symbols are shifted horizontally to prevent the error bars from overlapping. DAPA = dapagliflozin; INS = insulin; PLA = placebo.
Date of download: 5/13/2017
Copyright © American College of Physicians. All rights reserved.
From: Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of
InsulinA Randomized Trial
Ann Intern Med. 2012;156(6):405-415. doi:10.7326/0003-4819-156-6-201203200-00003
Figure Legend:
Appendix Figure
2. Probability of insulin up-titration due to not achieving prespecified glycemic targets or of discontinuation due to poor glycemic control over time.
Symbols represent censored observations. “Week” is the actual number of days from the first dose of double-blind study medication divided by 7, not the scheduled visit week. Values for patients at risk are for the
beginning of the period. DAPA = dapagliflozin; INS = insulin; PLA = placebo.
Date of download: 5/13/2017
Copyright © American College of Physicians. All rights reserved.
From: Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of
InsulinA Randomized Trial
Ann Intern Med. 2012;156(6):405-415. doi:10.7326/0003-4819-156-6-201203200-00003
Figure Legend:
Appendix Figure 3. Patients with events
suggesting genital infection (top) or urinary tract infection (bottom) at 24 and 48 weeks.
DAPA = dapagliflozin; INS = insulin; PLA = placebo.
Date of download: 5/13/2017
Copyright © American College of Physicians. All rights reserved.
From: Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of
InsulinA Randomized Trial
Ann Intern Med. 2012;156(6):405-415. doi:10.7326/0003-4819-156-6-201203200-00003
Figure Legend:
Appendix Figure 4.
Change in mean HbA1c level over time
calculated by using the placebo group to impute missing data in the safety analysis set and analyzed by treatment group and discontinuation status.
DAPA = dapagliflozin; HbA1c = hemoglobin
A1c; INS = insulin; PLA = placebo.
Date of download: 5/13/2017
Copyright © American College of Physicians. All rights reserved.